Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer

  title={Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer},
  author={Bette J. Caan and Jennifer A. Emond and Loki Natarajan and Adrienne L. Castillo and Erica P. Gunderson and Laurel A Habel and Lovell A Jones and Vicky A. Newman and Cheryl L. Rock and Martha L. Slattery and Marcia L Stefanick and Barbara Sternfeld and Cynthia A. Thomson and John P. Pierce},
  journal={Breast Cancer Research and Treatment},
SummaryPurposeTo examine whether weight gain after diagnosis of breast cancer affects the risk of breast cancer recurrence.Patient and methodsPatients included 3215 women diagnosed with early stage breast cancer (Stage I >1 cm., II, and IIIA) who were enrolled either in an observational cohort of breast cancer survivors or were part of the comparison group of a dietary intervention trial to prevent breast cancer recurrence. We computed weight change from 1 year prior to diagnosis to study… 

Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer

Being obese before breast cancer diagnosis was associated with increased risk of recurrence and poorer survival, corroborating results from previous studies and appearing to be the strongest predictor of an adverse breast cancer prognosis.

Weight Gain Prior to Diagnosis and Survival from Breast Cancer

It is indicated that high levels of prediagnostic weight and substantial weight gain throughout life can decrease survival in premenopausal and postmenopausal breast cancer patients.

Weight Change and Associated Factors in Long-Term Breast Cancer Survivors

Long-term breast cancer survivors who were non-obese at diagnosis are more likely to gain weight than obese survivors, and younger survivors and survivors who have never used AI are also likely to lose weight.

Weight Change and Survival after Breast Cancer in the After Breast Cancer Pooling Project

Background: Weight change after a breast cancer diagnosis has been linked to lower survival. To further understand effects of postdiagnostic weight variation on survival, we examined the relationship

Association between weight change and breast cancer prognosis

It is suggested that weight loss was detrimental to breast cancer prognosis, particularly for post-menopausal women, while weight gain may be a potential beneficial indicator for the patients with endocrine therapy but not for those with non-endocrine therapy.

A Prospective Study of Weight Gain in Women Diagnosed with Early-Stage Invasive Breast Cancer, Ductal Carcinoma In Situ, and Women Without Breast Cancer.

EIBC patients were more likely than DCIS patients and controls to experience ≥5% weight gain over follow-up, and studies are necessary to elucidate mechanisms of weight gain in early-stage breast cancer survivors.

Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse

The results suggest that weight change during breast-cancer chemotherapy treatment may be related to poorer prognosis with higher reccurence and higher mortality in comparison to women who maintained their weight.

Lifestyle Factors and the Risk of a Second Breast Cancer after Ductal Carcinoma In Situ

The results suggest that DCIS survivors may be able to reduce their risk of a second diagnosis through moderation of alcohol consumption, as well as other lifestyle factors, by reducing postdiagnosis alcohol consumption.

Association between weight gain during adjuvant chemotherapy for early‐stage breast cancer and survival outcomes

Weight variation during adjuvant chemotherapy for early‐stage breast cancer may occur as both weight gain and weight loss in a balanced manner and does not appear to significantly influence recurrence rates and overall survival.

Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population

These findings add to the growing evidence that obesity may contribute to poorer breast cancer outcomes, and also suggest that increased tumor proliferation among obese women is a pathway that explains part of their excess risk of adverse outcomes.



Weight, weight gain, and survival after breast cancer diagnosis.

Weight and weight gain were related to higher rates of breast cancer recurrence and mortality, but associations were most apparent in never-smoking women and in premenopausal than in postmenopausal women.

Weight loss in breast cancer patient management.

Although definitive weight loss intervention trials in breast cancer patients remain to be conducted, the current evidence relating increased body weight to adverse breast cancer outcome and the documented favorable effects of weight loss on clinical outcome in other comorbid conditions support consideration of programs for weight loss in Breast cancer patients.

Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Because obesity was associated with increased risks of contralateral breast cancer, of other primary cancers, and of overall mortality, it may influence long-term outcomes for breast cancer survivors and tamoxifen reduced breast cancer recurrence and mortality, regardless of BMI.

Body mass and stage of breast cancer at diagnosis

It is suggested that higher body mass is associated with advanced stage of breast cancer at diagnosis, given the increasing prevalence of obesity in women in the United States and the poor prognosis associated with late‐stage tumors.

Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group.

Weight gain in women with localized breast cancer — a descriptive study

It was concluded that the observed weight gain was not due to the use of adjuvant CMF and did not affect prognosis and further investigation was recommended to replicate the findings.

Weight gain in women diagnosed with breast cancer.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

  • G. BerclazS. Li A. Goldhirsch
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2004
BMI is an independent prognostic factor for OS in patients with breast cancer, especially among pre-/perimenopausal patients treated with chemotherapy without endocrine therapy, and among patients receiving chemotherapy alone.

Risk of menopause during the first year after breast cancer diagnosis.

Age and systemic chemotherapy are the strongest predictors of menopause in women with locoregional breast cancer as well as planned adjuvant treatment, and it may facilitate clinical decision-making.

Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.

It is concluded that, relative to observation, adjuvant chemotherapy is associated with greater weight gain in node-positive, postmenopausal breast cancer patients, and in premenopausal women, excessive weight gain may be associated with an increase in relapse and cancer-related deaths in the selected patients who show no evidence of recurrence during 60 weeks of adjUvant chemotherapy.